Novo Nordisk Prepares to Launch Oral Weight Loss Pill as Clinical Data Shows Efficacy
Novo Nordisk is advancing toward regulatory approval for a 25-milligram oral version of its weight loss drug Wegovy, with potential clearance by year-end. New trial data demonstrates the pill's safety and metabolic benefits, mirroring results from injectable formulations.
The OASIS 4 trial revealed 71.1% of prediabetic patients achieved normal blood sugar levels after 64 weeks—more than double the placebo group's 33.3%. Significant weight loss correlated with improved cardiovascular markers including blood pressure and triglyceride levels.
Notably, the therapy showed consistent efficacy across demographic groups. Pre-menopausal women achieved 18.2% average body weight reduction, with comparable results for peri- and post-menopausal cohorts. The data strengthens the case for oral administration as an alternative to injections.
